Kirsten Bibbins-Domingo1, David C Grossman2, Susan J Curry3, Linda Bauman4, Karina W Davidson5, John W Epling6, Francisco A R García7, Jessica Herzstein8, Alex R Kemper9, Alex H Krist10, Ann E Kurth11, C Seth Landefeld12, Carol M Mangione13, William R Phillips14, Maureen G Phipps15, Michael P Pignone16. 1. University of California, San Francisco. 2. Group Health Research Institute, Seattle, Washington. 3. University of Iowa, Iowa City. 4. University of Wisconsin-Madison. 5. Columbia University, New York, New York. 6. State University of New York Upstate Medical University, Syracuse. 7. Pima County Department of Health, Tucson, Arizona. 8. Independent consultant, Washington, DC. 9. Duke University, Durham, North Carolina. 10. Fairfax Family Practice Residency, Fairfax, Virginia11Virginia Commonwealth University, Richmond. 11. Yale University, New Haven, Connecticut. 12. University of Alabama at Birmingham. 13. University of California, Los Angeles. 14. University of Washington, Seattle. 15. Brown University, Providence, Rhode Island. 16. University of Texas at Austin.
Abstract
IMPORTANCE: Tuberculosis remains an important preventable disease in the United States. An effective strategy for reducing the transmission, morbidity, and mortality of active disease is the identification and treatment of latent tuberculosis infection (LTBI) to prevent progression to active disease. OBJECTIVE: To issue a current US Preventive Services Task Force (USPSTF) recommendation on screening for LTBI. EVIDENCE REVIEW: The USPSTF reviewed the evidence on screening for LTBI in asymptomatic adults seen in primary care, including evidence dating from the inception of searched databases. FINDINGS: The USPSTF found adequate evidence that accurate screening tests for LTBI are available, treatment of LTBI provides a moderate health benefit in preventing progression to active disease, and the harms of screening and treatment are small. The USPSTF has moderate certainty that screening for LTBI in persons at increased risk for infection provides a moderate net benefit. CONCLUSIONS AND RECOMMENDATION: The USPSTF recommends screening for LTBI in populations at increased risk. (B recommendation).
IMPORTANCE: Tuberculosis remains an important preventable disease in the United States. An effective strategy for reducing the transmission, morbidity, and mortality of active disease is the identification and treatment of latent tuberculosis infection (LTBI) to prevent progression to active disease. OBJECTIVE: To issue a current US Preventive Services Task Force (USPSTF) recommendation on screening for LTBI. EVIDENCE REVIEW: The USPSTF reviewed the evidence on screening for LTBI in asymptomatic adults seen in primary care, including evidence dating from the inception of searched databases. FINDINGS: The USPSTF found adequate evidence that accurate screening tests for LTBI are available, treatment of LTBI provides a moderate health benefit in preventing progression to active disease, and the harms of screening and treatment are small. The USPSTF has moderate certainty that screening for LTBI in persons at increased risk for infection provides a moderate net benefit. CONCLUSIONS AND RECOMMENDATION: The USPSTF recommends screening for LTBI in populations at increased risk. (B recommendation).
Authors: Anthony T Fojo; Natalie L Stennis; Andrew S Azman; Emily A Kendall; Sourya Shrestha; Shama D Ahuja; David W Dowdy Journal: Lancet Public Health Date: 2017-07
Authors: Lisa A Ronald; Jonathon R Campbell; Caren Rose; Robert Balshaw; Kamila Romanowski; David Z Roth; Fawziah Marra; Kevin Schwartzman; Victoria J Cook; James C Johnston Journal: Clin Infect Dis Date: 2019-11-27 Impact factor: 9.079
Authors: Constance A Benson; Judith S Currier; Carlos Del Rio; Joel E Gallant; Roy M Gulick; Jeanne M Marrazzo; Douglas D Richman; Michael S Saag; Robert T Schooley; Paul A Volberding Journal: Top Antivir Med Date: 2017 Dec/Jan
Authors: Suzanne M Marks; David W Dowdy; Nicolas A Menzies; Priya B Shete; Joshua A Salomon; Andrea Parriott; Sourya Shrestha; Jennifer Flood; Andrew N Hill Journal: Public Health Rep Date: 2020 Jul/Aug Impact factor: 2.792
Authors: M V Aslam; K Owusu-Edusei; S M Marks; G R B Asay; R Miramontes; M Kolasa; C A Winston; P M Dietz Journal: Int J Tuberc Lung Dis Date: 2018-12-01 Impact factor: 2.373
Authors: Mark L Wieland; Julie A Nigon; Jennifer A Weis; Leah Espinda-Brandt; Dawn Beck; Irene G Sia Journal: J Public Health Manag Pract Date: 2019 Nov/Dec
Authors: Maryam B Haddad; Timothy L Lash; Kenneth G Castro; Andrew N Hill; Thomas R Navin; Neel R Gandhi; Matthew J Magee Journal: Am J Prev Med Date: 2020-02-13 Impact factor: 5.043
Authors: Robert Belknap; David Holland; Pei-Jean Feng; Joan-Pau Millet; Joan A Caylà; Neil A Martinson; Alicia Wright; Michael P Chen; Ruth N Moro; Nigel A Scott; Bert Arevalo; José M Miró; Margarita E Villarino; Marc Weiner; Andrey S Borisov Journal: Ann Intern Med Date: 2017-11-07 Impact factor: 25.391